Breakeven Date Change • May 09
Forecast breakeven date pushed back to 2024 The 9 analysts covering Diversey Holdings previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 74% to 2023. The company is expected to make a profit of US$61.4m in 2024. Average annual earnings growth of 110% is required to achieve expected profit on schedule. Reported Earnings • May 05
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2023 results: US$0.17 loss per share (further deteriorated from US$0.12 loss in 1Q 2022). Revenue: US$696.0m (up 5.5% from 1Q 2022). Net loss: US$53.6m (loss widened 37% from 1Q 2022). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 141%. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in the US. Major Estimate Revision • Apr 06
Consensus EPS estimates increase from loss to US$0.062 profit The consensus outlook for fiscal year 2023 has been updated. 2023 forecast for profit of -US$0.04 instead of a loss of US$0.062 per share previously. Revenue forecast unchanged at US$2.91b. Chemicals industry in the US expected to see average net income growth of 11% next year. Consensus price target broadly unchanged at US$8.41. Share price was steady at US$8.11 over the past week. Breakeven Date Change • Mar 20
Forecast breakeven date pushed back to 2024 The 9 analysts covering Diversey Holdings previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 92% to 2023. The company is expected to make a profit of US$63.0m in 2024. Average annual earnings growth of 118% is required to achieve expected profit on schedule. Reported Earnings • Mar 19
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: US$0.53 loss per share (improved from US$0.60 loss in FY 2021). Revenue: US$2.77b (up 5.6% from FY 2021). Net loss: US$169.3m (loss narrowed 3.1% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 96%. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in the US. Price Target Changed • Mar 09
Price target increased by 15% to US$7.95 Up from US$6.90, the current price target is an average from 10 analysts. New target price is approximately in line with last closing price of US$8.14. Stock is up 5.4% over the past year. The company is forecast to post a net loss per share of US$0.27 next year compared to a net loss per share of US$0.60 last year. Price Target Changed • Nov 16
Price target decreased to US$7.17 Down from US$8.55, the current price target is an average from 11 analysts. New target price is 33% above last closing price of US$5.38. Stock is down 62% over the past year. The company is forecast to post a net loss per share of US$0.27 next year compared to a net loss per share of US$0.60 last year. Board Change • Nov 16
High number of new and inexperienced directors There are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. No experienced directors. No highly experienced directors. Independent Director Michel G. Plantevin is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Price Target Changed • Nov 07
Price target decreased to US$7.17 Down from US$8.55, the current price target is an average from 11 analysts. New target price is 33% above last closing price of US$5.38. Stock is down 68% over the past year. The company is forecast to post a net loss per share of US$0.34 next year compared to a net loss per share of US$0.60 last year. Reported Earnings • Nov 04
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: US$0.11 loss per share (improved from US$0.14 loss in 3Q 2021). Revenue: US$689.0m (up 3.6% from 3Q 2021). Net loss: US$36.5m (loss narrowed 13% from 3Q 2021). Revenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Chemicals industry in the US. Annonce • Nov 04
Diversey Holdings, Ltd. Provides Earnings Guidance for the Year 2022 Diversey Holdings, Ltd. provided earnings guidance for the year 2022. Updating 2022 full year revenue outlook to mid-single digit percent growth over 2021. Annonce • Nov 03
Diversey Holdings, Ltd. Announces Executive Changes On October 31, 2022, Jonathon Penn informed the board of directors of Diversey Holdings, Ltd. (the Company) of his intention to resign his position on the Board, effective November 1, 2022. The company expresses gratitude to Mr. Penn for his contributions to the Board and the Company. Mr. Penn's departure is not related to any disagreement with the Company or the Board regarding any matter related to the Company's operations, policies or practices. On November 1, 2022, the Board appointed Emily Ashworth to fill the vacancy on the Board resulting from the resignation of Mr. Penn, due to her broad experience as a Chief Information Officer and Chief Technology Officer, her experience in the private equity industry, as well as her perspective as a representative of shareholder, with such appointment effective on November 1, 2022. Ms. Ashworth is not expected to receive compensation for service as a member of the Board. The Board does not currently plan to appoint Ms. Ashworth to any committees of the Board. Ms. Ashworth was nominated by Bain Capital to serve as a member of the Board pursuant to the Investor Rights Agreement dated March 29, 2021 among the Company, Bain Capital and the other shareholders identified therein. Ms. Ashworth has a B.Sc. in Industrial Engineering and a B.Sc. in Liberal Studies from the University of Central Florida, and a M.Sc. in Industrial Engineering from the University of Tennessee. Annonce • Oct 14
Diversey Holdings, Ltd. to Report Q3, 2022 Results on Nov 03, 2022 Diversey Holdings, Ltd. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 03, 2022 Major Estimate Revision • Oct 12
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.14 to -US$0.19 per share. Revenue forecast unchanged at US$2.81b. Chemicals industry in the US expected to see average net income growth of 23% next year. Consensus price target down from US$9.66 to US$8.82. Share price fell 9.8% to US$4.32 over the past week. Buying Opportunity • Oct 12
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 31%. The fair value is estimated to be US$5.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.1% over the last year. Earnings per share has grown by 20%. Revenue is forecast to grow by 5.6% in a year. Earnings is forecast to grow by 97% in the next year. Buying Opportunity • Sep 21
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 37%. The fair value is estimated to be US$6.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.1% over the last year. Earnings per share has grown by 20%. Revenue is forecast to grow by 6.7% in a year. Earnings is forecast to grow by 97% in the next year. Price Target Changed • Sep 06
Price target decreased to US$9.45 Down from US$10.45, the current price target is an average from 10 analysts. New target price is 64% above last closing price of US$5.78. Stock is down 66% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$0.60 last year. Reported Earnings • Aug 05
Second quarter 2022 earnings: EPS misses analyst expectations Second quarter 2022 results: US$0.11 loss per share (down from US$0.004 loss in 2Q 2021). Revenue: US$715.3m (up 10.0% from 2Q 2021). Net loss: US$34.2m (loss widened US$32.9m from 2Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 404%. Over the next year, revenue is forecast to grow 7.3%, compared to a 10% growth forecast for the industry in the US. Annonce • Aug 05
Diversey Holdings, Ltd. Provides Revenue Guidance for the Third Quarter and Full Year of 2022 Diversey Holdings, Ltd. provided revenue guidance for the third quarter and full year of 2022. For the quarter, company estimates for revenue to be in a range of $680 million to $720 million.For the year, the company expects high single-digit percentage revenue growth. Annonce • Jul 18
Diversey Holdings Announces New Study from Diversey Shows That Certain Reusable Respirators Are Highly Compatible with Proven Disinfectants Even in Conditions of Extreme Exposure Diversey Holdings, Ltd. announced a result of the COVID pandemic, there has been a scarcity of single-use face masks/respirators for healthcare workers in manyfacilities. Healthcare facilities are increasingly providing Powered Air-Purifying Respirators (PAPRs) for staff use, but there has been limited information on the impact of routine cleaning and disinfection in addition to potential damage to PAPR components. This study, conducted by Diversey's Global Infection Prevention Application Experts and published in the Journal of Occupational and Environmental Hygiene investigated the risk of damage to PAPR components from routine disinfection and found that commonly used PAPRs are highly compatible with certain disinfectants even in conditions of extreme exposure, demonstrating a low risk of damage to PAPR components from routine disinfection for the tested disinfectants even after a high number of disinfection events. The study built on Diversey's prior research into the impact of routine cleaning and disinfection on personal protective equipment (PPE) used in healthcare. Annonce • Jul 12
Diversey Holdings, Ltd. to Report Q2, 2022 Results on Aug 04, 2022 Diversey Holdings, Ltd. announced that they will report Q2, 2022 results Pre-Market on Aug 04, 2022 Annonce • Jun 26
Diversey Holdings, Ltd.(NasdaqGS:DSEY) dropped from Russell 2500 Value Index Diversey Holdings, Ltd.(NasdaqGS:DSEY) dropped from Russell 2500 Value Index Buying Opportunity • Jun 13
Now 20% undervalued Over the last 90 days, the stock is up 17%. The fair value is estimated to be US$10.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Earnings per share has grown by 32%. Breakeven Date Change • May 21
Forecast breakeven date moved forward to 2022 The 10 analysts covering Diversey Holdings previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$11.9m in 2022. Earnings growth of 88% is required to achieve expected profit on schedule. Recent Insider Transactions • May 18
Independent Non-Executive Chairman recently bought US$1.1m worth of stock On the 13th of May, Eric Foss bought around 121k shares on-market at roughly US$8.67 per share. This was the largest purchase by an insider in the last 3 months. This was Eric's only on-market trade for the last 12 months. Price Target Changed • May 13
Price target decreased to US$11.18 Down from US$12.09, the current price target is an average from 10 analysts. New target price is 25% above last closing price of US$8.94. Stock is down 47% over the past year. The company is forecast to post earnings per share of US$0.037 next year compared to a net loss per share of US$0.60 last year. Annonce • May 12
Diversey Holdings, Ltd. Reaffirms Revenue Guidance for the Full Year 2022 Diversey Holdings, Ltd. reaffirmed revenue guidance for the full year 2022. For the year, the company expects high single digit percentage revenue growth. Breakeven Date Change • May 11
Forecast breakeven date pushed back to 2023 The 10 analysts covering Diversey Holdings previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 93% to 2022. The company is expected to make a profit of US$110.2m in 2023. Average annual earnings growth of 105% is required to achieve expected profit on schedule. Reported Earnings • May 10
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: US$0.12 loss per share (up from US$0.39 loss in 1Q 2021). Revenue: US$660.0m (up 4.5% from 1Q 2021). Net loss: US$39.1m (loss narrowed 59% from 1Q 2021). Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) missed analyst estimates by 311%. Over the next year, revenue is forecast to grow 7.6%, compared to a 12% growth forecast for the industry in the US. Board Change • Apr 27
High number of new and inexperienced directors There are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. No experienced directors. No highly experienced directors. Independent Director Michel G. Plantevin is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annonce • Apr 20
Diversey Holdings, Ltd. to Report Q1, 2022 Results on May 10, 2022 Diversey Holdings, Ltd. announced that they will report Q1, 2022 results Pre-Market on May 10, 2022 Breakeven Date Change • Mar 15
Forecast breakeven date pushed back to 2023 The 10 analysts covering Diversey Holdings previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 89% to 2022. The company is expected to make a profit of US$132.7m in 2023. Average annual earnings growth of 141% is required to achieve expected profit on schedule. Reported Earnings • Mar 11
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: US$0.60 loss per share (down from US$0.20 loss in FY 2020). Revenue: US$2.62b (flat on FY 2020). Net loss: US$174.8m (loss widened 354% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 62%. Over the next year, revenue is forecast to grow 7.6%, compared to a 12% growth forecast for the industry in the US. Annonce • Mar 03
Diversey Holdings, Ltd. Appoints Katherine S. Zanotti to Board of Directors Diversey Holdings, Ltd. has appointed Katherine S. Zanotti to the company’s board of directors, effective March 1, 2022. This appointment will bring the total number of directors to eleven. Katherine S. Zanotti served as Chief Executive Officer of Arbonne International, a skin care, cosmetic and nutrition company, from 2009 until 2018. Prior to Arbonne, Ms. Zanotti served as Senior Vice President of Marketing at McDonald's Corporation, and earlier in her career Ms. Zanotti held a variety of roles at Procter & Gamble, ultimately as Vice President and General Manager of its North American pharmaceutical business. Ms. Zanotti currently serves on the boards of Cutera Inc. and Exact Sciences Corp. as well as the Board of Trustees of Xavier University. Annonce • Feb 18
Diversey Holdings, Ltd., Annual General Meeting, May 04, 2022 Diversey Holdings, Ltd., Annual General Meeting, May 04, 2022, at 10:00 US Eastern Standard Time. Location: 1300 Altura Road, Suite 125, Fort Mill, South Carolina 29708 Fort Mill United States Agenda: Annual General Meeting. Annonce • Feb 08
Diversey Holdings, Ltd. to Report Q4, 2021 Results on Mar 09, 2022 Diversey Holdings, Ltd. announced that they will report Q4, 2021 results Pre-Market on Mar 09, 2022 Annonce • Jan 25
Diversey Holdings, Ltd. (NasdaqGS:DSEY) acquired Shorrock Trichem Limited. Diversey Holdings, Ltd. (NasdaqGS:DSEY) acquired Shorrock Trichem Limited on January 24, 2022. Diversey pleased to welcome Shorrock’s 240 experienced colleagues to Diversey. Acquisition expands portfolio of products and services, including innovative sustainability solutions, Enhances Diversey’s sales and service capabilities through Shorrock’s experienced employees and distribution infrastructure, allowing for improved customer service, Extends strategy to acquire great businesses that enhance strategic capabilities and strengthen key geographies at accretive purchase multiples.
Diversey Holdings, Ltd. (NasdaqGS:DSEY) completed the acquisition of Shorrock Trichem Limited on January 24, 2022. Buying Opportunity • Jan 22
Now 25% undervalued after recent price drop Over the last 90 days, the stock is down 36%. The fair value is estimated to be US$14.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 60% per annum over the last 3 years. Annonce • Dec 07
Diversey Holdings, Ltd. (NasdaqGS:DSEY) acquired Birko Corporation from Kelly Green family Diversey Holdings, Ltd. (NasdaqGS:DSEY) acquired Birko Corporation from Kelly Green family on December 6, 2021.
Diversey Holdings, Ltd. (NasdaqGS:DSEY) completed the acquisition of Birko Corporation from Kelly Green family on December 6, 2021. Annonce • Dec 01
Diversey's New IntelliCIP Platform Uncovers Deep Data Insights to Optimise CIP Performance Diversey launched its IntelliCIP (Clean-in-Place) cloud-based data analytics platform globally. IntelliCIP securely collates and processes Food and Beverage (F&B) production CIP data for rapid insight into hygiene compliance and operational performance. By analysing and monitoring selected data points, a production facility can easily access a quick view of CIP processes for any date range, specific unit, CIP circuit, or recipe, to truly understand if the process is in control - then act on results if compliance with defined (validated) parameters has not been met. IntelliCIP helps ensure food safety, quality, and traceability by unlocking information typically buried within the automation system, or manual tracking results. Before IntelliCIP, identifying the use of excess resources, or a contamination risk from unmet hygiene parameters, has been largely unexplored. Measuring the True Effectiveness of Each CIP Run: IntelliCIP's easy-to-use interface can show where a CIP may be resulting in lost resources. Data is automatically collected and analysed to provide proof of compliance with the cleaning protocols, alongside progressively revealed indicators and opportunities identifying where the process can be optimised. Cleaning run reports enable swift corrective action to ensure food safety, and improve operational efficiency and sustainability, with expectation of driving recipe repeatability. Statistical analysis reveals cleaning run variance over time, allowing focused data-driven improvements, while providing more confidence that there's no negative effect on the cleaning result. IntelliCIP's continuous process monitoring gives facilities the control to ensure hygienic target compliance, an overview of chemical and utilities - to track water, energy, and chemical consumption - and the ability to manage their KPIs for food safety, efficiency, and quality improvements. Reported Earnings • Nov 06
Third quarter 2021 earnings released: US$0.14 loss per share The company reported a soft third quarter result with weaker control over costs, although losses were stable and revenues were flat. Third quarter 2021 results: Revenue: US$664.9m (flat on 3Q 2020). Net loss: US$42.1m (flat on 3Q 2020). Annonce • Aug 06
Diversey Holdings, Ltd. (NasdaqGS:DSEY) agreed to acquire Tasman Chemicals Pty. Limited from Peter Keech family. Diversey Holdings, Ltd. (NasdaqGS:DSEY) agreed to acquire Tasman Chemicals Pty. Limited from Peter Keech family on August 5, 2021. Breakeven Date Change • Jun 17
Forecast breakeven pushed back to 2022 The 9 analysts covering Diversey Holdings previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of US$191.7m in 2022. Average annual earnings growth of 93% is required to achieve expected profit on schedule.